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Abstract Effective combination antiretroviral therapy (cART)
has lead to a significant reduction in the prevalence and inci-
dence of central nervous system (CNS) HIV-associated brain
disease, particularly CNS opportunistic infections and HIVen-
cephalitis. Despite this, cognitive deficits in people living with
HIV, also known as HIV-associated neurocognitive disorders
(HAND) have become more prevalent in recent years. The
pathogenesis of HAND is likely to be multifactorial, however
recent evidence suggests that brain microglial activation is the
most likely pathogenic mechanism. Recent developments in
positron emission tomography (PET) brain neuroimaging
using novel brain radioligands targeting a variety of physiolog-
ical changes in the brains of HIV-positive individuals have
improved our understanding of the mechanisms associated
with the development of HAND. This review will highlight
recent PET brain neuroimaging studies in the cART era, focus-
ing on physiological and neurochemical changes associated
with HAND in people living with HIV.
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Introduction
The introduction of effective combination antiretroviral
(cART) therapy has led to dramatic reductions in the incidence
and prevalence of HIV-associated central nervous system
(CNS) opportunistic infections and HIV encephalopathy [1,
2]. Despite the significant impact of cART on HIV-
associated CNS disease, clinically significant cognitive defi-
cits affecting people living with HIV have become increasing-
ly apparent in recent years [3]. Prevalence rates of HIV-
associated neurocognitive disorders, also known as HAND
of between 15 to 50% have been observed across clinical
and geographical settings, with effectively treated HIV-
positive individuals having a higher prevalence of cognitive
impairment compared to the general population [4–9]. HAND
diagnosis is based on neuropsychometric testing and includes
asymptomatic neurocognitive impairment (ANI), mild
neurocognitive impairment (MCI), and the most severe form,
HIV-associated dementia (HAD) [10]. In countries where
cART is widely available, HIV-associated dementia has dra-
matically declined, however milder forms of cognitive impair-
ment persist despite the availability of potent cART. HAND in
people living with HIV has several possible pathogenic mech-
anisms including poor drug concentration of antiretrovirals in
CNS, legacy effect of CNS damage sustained during early
stages of HIV infection of the brain, antiretroviral neurotoxic-
ity, persistent brain immune activation, and comorbidities
such as cerebrovascular disease, syphilis, and hepatitis C co-
infection [11–18].
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Neuroimaging techniques that evaluate brain structure,
metabolism, neurochemistry, and brain function have been
used widely in clinical settings to aid in the diagnosis, and
description of neurological disorders associated with HIV.
Recent technical advances in these techniques offer new
perspectives for studying the neuropathogenesis of HIV-
associated brain disease in the era of cART. Positron emis-
sion tomography (PET) is now well established for clinical
use in neurodegenerative disorders, especially in the diagno-
sis of dementia. The development of PET brain radiotracers
that allow imaging of neuroinflammation, functional activity,
neurotransmitter systems, and amyloid plaque deposition
might have the potential to advance our knowledge of the
pathophysiology of HAND. This review will highlight PET
radiotracers used to study HIV-associated brain disease, fo-
cusing on PET neuroimaging studies that have contributed
to our understanding of HAND in the era of combination
antiretroviral therapy (Table 1).
PET-FDG brain imaging in HAND
Fluorodeoxyglucose [18F]-FDG PET brain imaging has been
widely used in clinical and research settings for the evaluation
of several neurological diseases, including HIV-associated
brain diseases [30]. [18F]-FDG PET allows the in vivo quan-
tification of cerebral glucose metabolism, which reflects neu-
ronal and synaptic activity. [18F]-FDG PET has the ability to
quantify regional differences in cerebral glucose metabolism,
which can provide information about the distribution and ac-
tivation of brain patterns. [18F]-FDG PET has proven to be
useful as a diagnostic tool in the clinical evaluation of CNS
lesions in patients with HIV, particularly in those with CNS
opportunistic infections where [18F]-FDG PET can be used to
distinguish between CNS malignancy and infection [31, 32].
[18F]-FDG PET has also been used to explore regional cere-
bral glucose metabolism patterns in HIV-positive patients with
and without cognitive impairment. Early pre-cART studies
using [18F]-FDG PET have shown consistently the presence
of subcortical hypermetabolism in the basal ganglia, striatum,
and thalamus of HIV-positive patients with early stages of
HIV-associated dementia, as well as asymptomatic HIV-
positive individuals, suggesting that increased glucose metab-
olism of subcortical structures, like the basal ganglia, are char-
acteristic of HAND in patients without cART [33, 34]. A
limited number of studies have investigated the impact of
cART on cerebral glucose metabolism using [18F]-FDG
PET. They have demonstrated changes in [18F]-FDG PET
uptake despite effective virological suppression with cART.
Changes include reductions in [18F]-FDG PET uptake in fron-
tal regions in HIV-positive patients without cognitive impair-
ment [19], and subtle basal ganglia hypermetabolism despite
virological control with cART [20]. In summary, [18F]-FDG
PET is helpful in the clinical evaluation of HIV positive pa-
tients with space-occupying lesions demonstrated on MRI or
CT. However, the role of [18F]-FDG PET in the clinical as-
sessment of HAND is less clear, as [18F]-FDG PET brain
uptake correlates poorly with clinical and cognitive parame-
ters in patients with different forms of HAND. Further re-
search is needed to determine the role of [18F]-FDG PET in
this context.
PET imaging of neurotransmitters in HAND
The presence of acute-onset parkinsonism in HIV-positive
patients with HIV-associated dementia suggested a vulnera-
bility of the dopaminergic system to the effects of HIV in-
fection of the brain [35, 36]. This clinical observation was
followed by reports of hypersensitivity to dopamine
blockers, and the reduced concentration of CSF dopamine
levels in HIV-positive patients with and without cognitive
deficits [37]. Histopathological and [18F]-FDG PET imaging
support the propensity of HIV-1 to affect basal ganglia struc-
tures [38, 39], which are known to have the highest density
of dopaminergic terminals. Dopamine function can be
assessed using PET imaging. [11C]-cocaine allows the as-
sessment of presynaptic dopaminergic transporters (DAT)
availability, while [11C]-raclopride measures D2 dopaminer-
gic receptor availability, which mostly reflects postsynaptic
sites [40]. Using these radioligands, Wang et al. found that
although there were no differences in D2 receptors between
HIV-positive patients and controls in any brain region, a
significant decrease in DAT availability was observed in
the putamen and ventral striatum of HIV-positive patients
with HIV-associated dementia compared with HIV-negative
controls. This small study (n = 15, HIV-positive individuals)
was the first to suggest that decreased DAT might contribute
towards the pathogenesis of HIV-associated dementia
(Fig. 1) [21]. These findings were validated in a larger co-
hort of HIV-positive patients (n = 35) with cognitive impair-
ment, but no HIV-associated dementia. In this study, com-
pared to HIV-negative controls, HIV-positive individuals
with cognitive impairment had reduced dopaminergic func-
tion (lower DAT), and this was associated with poorer cog-
nitive performance [22]. Interestingly, in both studies, de-
spite the significant decreases in dopaminergic function in
the basal ganglia structures, there were only mild motor
symptoms such as bradykinesia and rigidity, including inter-
mittent choreiform movements in only three HIV-positive
individuals with HIV-associated dementia. Further studies
are needed to determine the effect of cART on DAT and
D2 availability in HIV-positive individuals with and without
cognitive impairment and its relationship with cognitive
function.
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Table 1 Summary of PET studies in HAND in HIV-positive individuals on cART
Reference Subjects Radioligand
target and ligand
Brain regions evaluated cART in HIV subjects Findings in HIV-infected
subjects
FDG
Andersen et al.
2010 [19]
38 HIV+
asymptomatic
[18F]-FDG Whole brain HIV+ on cART, but median
plasma HIV RNA >50
copies/ml
Reductions in the metabolic
rate of glucose in the mesial
frontal cortices involving the
anterior cingulated cortex
Von Gissen et al.
2000 [20]
15 HIV+
asymptomatic
15 HIV–
[18F]-FDG
Dopamine
transporters and
receptors
ROI: basal ganglia,
thalamus, and
prefrontal cortex
HIV+ on cART, but median
plasma HIV RNA >50
copies/ml
Hypermetabolism in the basal
ganglia associated with
normal motor performance
in HIV+ vs. controls
Wang et al. 2004
[21]
15 HIV+ (10 with
HAD)
13 HIV–
[11C]-cocaine;
[11C]-raclopride
ROI: basal ganglia and
cerebellum
HIV+ on cART, but median
plasma HIV RNA >50
copies/ml
Reduced DAT in putamen and
ventral striatum in HIV+
with HAD vs. HIV–
Chang et al.
2008 [22]
35 HIV+
asymptomatic
14 HIV–
[11C]-cocaine;
[11C]-raclopride
ROI: basal ganglia and
cerebellum
HIV+ on cART, but only 9
HIV+ patients with
plasma HIV RNA <50
copies/ml
Reduced dopaminergic
function with lower DAT in
putamen and caudate in
HIV+. Lower DAT in
putamen associated with
poorer cognitive function
Aβ42-amyloid
Ances et al. 2010
[23]
10 HIV+
asymptomatic
20 HIV–
[11C]-PiB ROI: prefrontal, lateral
temporal, precuneus,
and gyrus rectus
No information on HIV+ on
cART but median plasma
HIV RNA >50 copies/ml
No evidence of fibrillar
Aβ42-amyloid amyloid
deposition
Ances et al. 2012
[24]
16 HIV+ (5 with
HAND; 11
asymptomatic)
19 HIV– (8
asymptomatic, 9
with AD)
[11C]-PiB ROI: prefrontal, lateral
temporal, precuneus,
and gyrus rectus
No information on HIV+ on
cART but median plasma
HIV RNA >50 copies/ml
No evidence of fibrillar
Aβ42-amyloid amyloid
deposition vs. HIV– and AD
Turner et al.
2016 [25]
1 HIV-positive with
HAND (case
report)
[18F]-florbetaben Whole brain HIVon cARTwith plasma
HIV RNA <50 copies/ml
Mild hypermetabolism in
bilateral basal ganglia, and
marked hypometabolism of
parietal including the posterior
cingulate and precuneus
TSPO
Wiley et al. 2006
[26]
12 HIV+ (6 with
HAND; 6
asymptomatic)
5 HIV– controls
[11C] PK11195 >10 ROI All on cART, 9 out 12 HIV+
with detectable plasma
viremia
No differences in ligand
binding between HIV+ and
controls
Hammoud et al.
2005 [27]
15 HIV+ (10 with
HAND; 3 with
HAD; 5
asymptomatic)
5 HIV– controls
[11C]-PK11195 8 cortical regions one
white matter
7 HIV+ on cART, 3 cART
naive
Higher ligand binding in:
thalamus, putamen,
temporal, frontal, and
occipital lobe
In HIV+ with NCI, and in
HIV+ individuals overall
when compared to controls
Garvey et al.
2013 [28]
9 HIV+
asymptomatic
8 HIV– controls
[11C]-PK11195 >10 template derived
ROI
Not described Higher ligand binding in:
Corpus callosum, anterior,
posterior cingulate, frontal
and temporal lobe in HIV+
asymptomatic compared to
controls
Coughlin et al.
2014 [29]
23 HIV+ (8
asymptomatic;
15 with HAND;
8 with HAD)
12 HIV– controls
[11C]-DPA-713 >10 ROI All on cARTwith plasma
HIV RNA <50 copies/ml
Higher ligand binding in white
matter, frontal cortex,
cingulate cortex and
supramarginal gyrus in
HIV+ with HAND vs. HIV–
Vera et al. (2016)
[18]
12 HIV+
asymptomatic
10 HIV– controls
[11C]-PBR28 Whole brain, and >10
region of interest
All on cARTwith plasma
HIV RNA <50 copies/ml
Higher ligand binding globally,
with greatest signal in the
parietal, occipital globes,
and the globus pallidus.
TSPO binding associated
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PET imaging of neuroinflammation in HAND
Chronic activation of brain microglia has been suggested to be
a major contributor towards HIV-associated brain disease
[41]. In HIV, activation of microglia has been associated with
several factors, including persistent low-level HIV RNA rep-
lication, reduced concentration of cART in the CSF, cART
neurotoxicity, co-infections (hepatitis C, syphilis) and lifestyle
factors (smoking alcohol and recreational drug use). All of
these factors might lead to activation of microglia despite ef-
fective control of HIV RNA with cART [42]. PET imaging
allows in vivo quantification of neuroinflammation by mea-
suring the density of the translocator protein 18 kDa (TSPO).
TSPO is highly expressed in the mitochondria of microglia
and astrocytes [43]. Following activation through host re-
sponses to cellular injury, microglia and astrocytes increase
expression of TSPO [44]. Increased binding of a TSPO
radioligand therefore provides a proxy measure of brain
microglial activation that can be assessed in vivo with PET.
Few studies have investigated microglial activation using
TSPO PET in people living with HIV, with the majority of
studies employing [11C]-PK11195, a first-generation TSPO
radioligand. The findings have been contradictory with some
studies demonstrating differences in [11C]-PK11195 binding
between HIV-positive individuals with and without cognitive
impairment [27, 45] and others showing no significant differ-
ences between groups [26]. Possible explanations for these
discrepancies could be related to the difficulties in making
accurate measures of brain binding with this Bfirst-generation^
ligand because of a lower proportion of the signal that arises
from specifically bound [11C]-PK11195 [46].
Second-generation TSPO radioligands such as [11C]-
DPA-713 and [11C]-PBR28 have higher affinity for TSPO
and significantly better sensitivity compared with [11C]
PK11195 [47]. One of the limitations of second-generation
radioligands is that affinity for the target protein is deter-
mined by the rs6971 single-nucleotide polymorphism
(SNP) in the TSPO gene [48, 49] that leads to an amino acid
substitution (Ala147Thr), which is associated with in vitro
affinity of TSPO in platelets [50, 51]. Three patterns of
TSPO binding phenotypes have been identified in humans:
high affinity binders (HABs) who are those subjects without
Fig. 1 Distribution volume ratio images of PET with 11C-cocaine (DA
transporter) at the level of the basal ganglia. A significant decrease in
DAT availability was observed in the putamen and ventral striatum of
HIV-positive patients with HIV-associated dementia compared with
HIV-negative controls. The images are scaled with respect to the
maximum value obtained in the control subject and presented using the
rainbow scale from [21] Wang et al. with permission
Table 1 (continued)
Reference Subjects Radioligand
target and ligand
Brain regions evaluated cART in HIV subjects Findings in HIV-infected
subjects
with white matter
abnormalities on DTI MRI
in HIV+ vs. HIV.
HAND HIV-associated cognitive disorders; HAD HIV-associated dementia; AD Alzheimer’s disease; ROI region of interest; DTI MRI diffusion tensor
imaging
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the polymorphism (HH), low affinity binders (LABs) who
are homozygotes (LL) and mixed affinity binders (MABs)
who are heterozygotes (HL) expressing both low- and high-
affinity binding to TSPO. HABs and LABs express a single
binding site for TSPO with either high or low affinity,
whereas MABs express equal amounts of HAB and LAB
binding sites. A genotype analysis in plasma is available to
characterize expected TSPO affinity that allows the incor-
poration of genotypic data enabling more accurate quanti-
tative interpretation of TSPO PET data [48]. Another limi-
tation relates to the TSPO itself. TSPO is regulated by a
number of physiological factors including stress, steroid,
and cholesterol metabolism, which can affect the analysis
of TSPO imaging studies, and might contribute to poor tests
reproducibility [29]. To control for some of these factors,
analysis of second-generation TSPO data using a brain re-
gion that serves as a region of reference has been suggested.
Brain regions of reference are selected because they are
believed to be brain regions were binding activity is non-
specific in the disease process studied, however when post-
mortem and receptor imaging studies are performed, a sig-
nificant percentage of specific binding is encountered, com-
plicating the interpretation of the data [52]. Studies using
this model of analysis have employed the gray matter be-
cause of the uniform pattern of binding displayed in healthy
subjects, but not HIV-positive patients using the first-
generation TSPO radioligand [11C] PK11195.
Two studies using Bsecond-generation^ TSPO radioligands
investigatedmicroglial activation in people livingwith HIVon
cART using the gray white matter (GM) as a region of refer-
ence. Coughlin et al. used [11C]-DPA-713 to evaluate regional
brain distribution of TSPO in HIV-positive patients compared
with seronegative controls [29]. The study compared 23 HIV-
positive individuals with and without HAND with 12 HIV-
negative controls. HIV-positive individuals demonstrated sig-
nificantly higher TSPO normalized volume of distribution
(VTGM) in the white matter, cingulate cortex, and the
supramarginal gyrus. An increase in TSPO VTGM within the
frontal cortex was specifically linked to individuals with HIV-
associated dementia. Using [11C]-PBR28 PET, Vera et al.
found evidence of increases in brain TSPO radioligand up-
take, with the greatest uptake of [11C]PBR28 in subcortical
brain grey matter, particularly in the basal ganglia (globus
pallidus, caudate and striatum) in a group of cognitively
healthy HIV-positive individuals without HAND and effec-
tive cART [18] (Fig. 2). In this study a significant relation-
ship between increased TSPO distribution volume ratios
VTDVR, in the basal ganglia and poorer cognitive perfor-
mance in tasks assessing verbal and visual memory was
observed, as well as white matter microstructural abnormal-
ities on diffusion tensor imaging MRI [18]. These findings
evidence that suggest that effective cART, HIV-positive pa-
tients microglial and possibly, astroglial activation is
present and that microglial activation could potentially lead
to the development of HIV-associated brain disease and
HAND. More research is required to determine the feasibil-
ity of using TSPO PET in the clinical assessment of patients
with HAND.
PET imaging of neuropathology in HAND
Neurodegeneration has been suggested as one the pathogenic
mechanisms associated with HAND. However, until recently,
it has not been possible to examine in vivo biomarkers of
neurodegeneration in HIV-positive patients effectively treated
with cART. The deposition of Aβ42−amyloid is considered a
key marker of neuronal degeneration in Alzheimer’s disease
(AD). Several reports have described a significant increase in
brain Aβ42-amyloid deposition in patients with acquired im-
munodeficiency syndrome (AIDS) in brain pathology follow-
ing post-mortem examinations [53, 54], as well as reductions
in Aβ42-amyloid in CSF of treated HIV-positive patients with
HAND [55–57], indicating increased deposition of Aβ42-
amyloid in brain parenchyma. With the improvements in life
expectancy of people living with HIV, increasing concerns
have arisen as to whether HIV-positive patients are at in-
creased risk of developing AD, and the challenges that clini-
cians will face differentiating between HAND and other neu-
rodegenerative disorders in aging HIV-infected populations.
The development of radiotracers such as the amyloid binding
Fig. 2 Volume of distribution parametric maps (0–90 min) of
[11C]PBR28 TSPO PET in a 55-year-old HIV-positive man without
cognitive impairment on the left and a 53-year-old control subject on
the right. Both individuals were high affinity binders. Images are
transverse, coronal, and sagittal, from top to bottom
Eur J Nucl Med Mol Imaging
agents [11C]-labeled Pittsburgh Compound B [11C]-PIB,
[18F]-flobetapir, [18F]-florbetaben, and [18F]-flutametamol of-
fer the possibility to measure in vivo, the degree and distribu-
tion of Aβ42-amyloid deposition in the brains of HIV-positive
individuals with cognitive impairment, and to distinguished
between HAND and AD. In HIV-negative individuals,
[11C]-PiB has demonstrated amyloid deposition in preclinical
AD [58]. Two studies have used [11C]-PiB in HIV-positive
individuals [23, 24] with unexpected results, as both studies
were unable to demonstrate the presence of amyloid accumu-
lation in patients with HAND. There are several possible ex-
planations for these results. First, [11C]-PiB has significantly
better affinity for fibrillar plaques rather than diffuse amyloid
plaques, which have been traditionally associated with
HAND. Second, there might be differences in amyloid metab-
olism between AD and HAND that [11C]-PiB is unable to
detect. Finally, relatively younger individuals were included
in these studies (the oldest was 67 years old) [59 ]. Indeed,
Turner et al. reported for the first time the presence of in vivo
amyloid deposition in a 71-year-old HIV-positive individual
with HAND using [18F]-florbetaben, which has better affinity
for diffuse amyloid plaques. [18F]-florbetaben PET CT
showed abnormal scan appearances with pronounced cortical
radiotracer deposition suggesting for the first time the pres-
ence of in vivo Aβ42-amyloid deposition in a person living
with HIV [25]. Further research is required to determine the
role of amyloid imaging in the clinical assessment of people
living with HIV with cognitive impairment.
Conclusions and future directions
The introduction of cART has dramatically changed the pat-
tern of brain disease associated with HIV infection. In settings
where cART is readily available, CNS opportunistic infections
and HIV-associated dementia are now rare, while patients on
effective treatment are presenting with cognitive symptoms
associated with HAND. This change in the natural history of
HIV-associated CNS brain disease along with an aging HIV
population at risk of neurodegenerative diseases generates
new challenges to clinicians and researchers alike, as defining
the cause of cognitive deficits in older HIV-positive patients
can be difficult, due to the multifactorial nature of HAND.
PET brain neuroimaging using novel radioligands might pro-
vide insight into different pathophysiological changes in the
brain, which then combined with other neuroimaging tech-
niques such as MRI could increase our knowledge of the
relationship between structural, chemical, and functional
changes in the brains of people living with HIV. In this re-
spect, radioligands targeting microglial and/or astrocyte acti-
vation may be of particular importance, as neuroinflammation
in HIVappears to be a major contributing factor for the devel-
opment of HAND [60, 61]. PET brain tracers targeting
inflammation, dopaminergic function, and possibly amyloid
deposition have the potential to both serve as biomarkers
supporting the diagnosis and management of HAND, and to
facilitate the evaluation of therapeutic interventions.
Considerably more research is needed to evaluate and estab-
lish the role of PET brain imaging techniques in the diagnosis
and management of HAND in people living with HIV.
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